Concepedia

Céline Boutry

CB

Statistics

Publications

5

Citations

424

H-Index

5

Active since

2020

Affiliations

GlaxoSmithKline (Belgium)(Current)

Universities at Shady Grove

Catholic University of Korea

Klinikum Würzburg Mitte

GlaxoSmithKline (United States)

Céline Boutry is an author at GlaxoSmithKline (Belgium) specializing in vaccine efficacy, immunization, and vaccine effectiveness.

ORCID

Publications per year

2020–2024

5

Publications

5

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

Michael G. Ison, Alberto Papi, Eugene Athan et al. · Clinical Infectious Diseases · 2024 · 162 citations · Full text

, , +17

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Ana Strezova, Javier Díez‐Domingo, Kamal Al Shawafi et al. · Open Forum Infectious Diseases · 2022 · 101 citations · Full text

, , +17

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Céline Boutry, Andrew Hastie, Javier Díez‐Domingo et al. · Clinical Infectious Diseases · 2021 · 93 citations · Full text

, , +17

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

Robert G. Feldman, Raffaele Antonelli Incalzi, Katie Steenackers et al. · Clinical Infectious Diseases · 2023 · 52 citations · Full text

, , +17

Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients

Josephine C Ocran-Appiah, Céline Boutry, Caroline Hervé et al. · Vaccine · 2020 · 16 citations · Full text

, , +17

1–5 of 5